Novartis
(https://lutathera.com) 📸 Data Snapshot: May 31, 2026Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
The site exhibits high information density with a low fluff-to-substance ratio. Specific technical data such as Ki-67 index ranges (10%–55%) and histological grading (grade 2 or 3) provide clinical weight to the claims. The primary value proposition—treating 20,000+ patients—is a concrete number that moves beyond generic ‘pioneering’ claims, though it is repeated across all crawled pages, resulting in a minor penalty for concept repetition.
Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.
📝 The Narrative — clean text per page (the substance-vs-filler signal)
HOMEPAGE (https://lutathera.com) GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: An older woman stands in a white room, smiling into the distance. She has her hand raised in a high-five, and many hands reach out from the side to return the high-five. The headline next to her says: YOU GOT THIS 20,000+ patients chose LUTATHERA for the opportunity to delay NET progression––join in their strength The footnote next to her reads: Actor portrayal.] [H4] LUTATHERA has helped treat over 20,000 patients with NETs, including those: Who have just been diagnosed with faster-growing NETs (Ki-67, 10%–55% [grade 2 or 3]) and are ready for their first treatmentWho added LUTATHERA to their treatment after progressing on SSAs [H4] LUTATHERA can help slow down NET progression for longer. Choosing the right first treatment for you is a big step after diagnosis. You and your doctor can decide if LUTATHERA is the right first step to slow NET progression.See proven results with LUTATHERA [IMG: Early action icon.] [H2] Acting early to slow NETs is an important first stepSee why >NET, neuroendocrine tumor; SSAs, somatostatin analogues.
SUB-PAGE (https://lutathera.com/patient-support/find-a-treatment-site/) GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: An older woman stands in a white room, smiling into the distance. She has her hand raised in a high-five, and many hands reach out from the side to return the high-five. The headline next to her says: YOU GOT THIS 20,000+ patients chose LUTATHERA for the opportunity to delay NET progression––join in their strength The footnote next to her reads: Actor portrayal.] [H4] LUTATHERA has helped treat over 20,000 patients with NETs, including those: Who have just been diagnosed with faster-growing NETs (Ki-67, 10%–55% [grade 2 or 3]) and are ready for their first treatmentWho added LUTATHERA to their treatment after progressing on SSAs [H4] LUTATHERA can help slow down NET progression for longer. Choosing the right first treatment for you is a big step after diagnosis. You and your doctor can decide if LUTATHERA is the right first step to slow NET progression.See proven results with LUTATHERA [IMG: Early action icon.] [H2] Acting early to slow NETs is an important first stepSee why >NET, neuroendocrine tumor; SSAs, somatostatin analogues.
SUB-PAGE (https://lutathera.com/about-gep-net/early-action/) GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: An older woman stands in a white room, smiling into the distance. She has her hand raised in a high-five, and many hands reach out from the side to return the high-five. The headline next to her says: YOU GOT THIS 20,000+ patients chose LUTATHERA for the opportunity to delay NET progression––join in their strength The footnote next to her reads: Actor portrayal.] [H4] LUTATHERA has helped treat over 20,000 patients with NETs, including those: Who have just been diagnosed with faster-growing NETs (Ki-67, 10%–55% [grade 2 or 3]) and are ready for their first treatmentWho added LUTATHERA to their treatment after progressing on SSAs [H4] LUTATHERA can help slow down NET progression for longer. Choosing the right first treatment for you is a big step after diagnosis. You and your doctor can decide if LUTATHERA is the right first step to slow NET progression.See proven results with LUTATHERA [IMG: Early action icon.] [H2] Acting early to slow NETs is an important first stepSee why >NET, neuroendocrine tumor; SSAs, somatostatin analogues.
SUB-PAGE (https://lutathera.com/sitemap/) GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: An older woman stands in a white room, smiling into the distance. She has her hand raised in a high-five, and many hands reach out from the side to return the high-five. The headline next to her says: YOU GOT THIS 20,000+ patients chose LUTATHERA for the opportunity to delay NET progression––join in their strength The footnote next to her reads: Actor portrayal.] [H4] LUTATHERA has helped treat over 20,000 patients with NETs, including those: Who have just been diagnosed with faster-growing NETs (Ki-67, 10%–55% [grade 2 or 3]) and are ready for their first treatmentWho added LUTATHERA to their treatment after progressing on SSAs [H4] LUTATHERA can help slow down NET progression for longer. Choosing the right first treatment for you is a big step after diagnosis. You and your doctor can decide if LUTATHERA is the right first step to slow NET progression.See proven results with LUTATHERA [IMG: Early action icon.] [H2] Acting early to slow NETs is an important first stepSee why >NET, neuroendocrine tumor; SSAs, somatostatin analogues.
🧭 Industry Context — common generic-claim patterns in Medical Devices, Pharma & Biotech to weigh the text against
This page presents a snapshot of public data from Novartis, captured on May 31, 2026, to show how machine logic reads Information Density signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Novartis: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://lutathera.com to view the most current version of its content and see directly what this company is about and what it offers.